TY - JOUR T1 - <sup>18</sup>F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1269 LP - 1275 DO - 10.2967/jnumed.116.175596 VL - 57 IS - 8 AU - Geraldine J. Liao AU - Amy S. Clark AU - Erin K. Schubert AU - David A. Mankoff Y1 - 2016/08/01 UR - http://jnm.snmjournals.org/content/57/8/1269.abstract N2 - Estrogen receptor (ER) expression in breast cancer is associated with a more favorable prognosis and is necessary for a response to endocrine therapies. Traditionally, ER expression is assessed by in vitro assays on biopsied tumor tissue. However, recent advances have allowed in vivo evaluation of ER expression with 18F-fluoroestradiol (18F-FES) PET. Clinical studies have demonstrated the use of 18F-FES PET as a method for quantifying in vivo ER expression and have explored its potential as a predictive assay and method of assessing in vivo pharmacodynamic response to endocrine therapy. This review outlines the biology and pharmacokinetics of 18F-FES, highlights the current experience with 18F-FES in patient studies on breast cancer and other diseases, and discusses potential clinical applications and the possible future clinical use of 18F-FES PET. ER -